ArticleJournal of the American Chemical Society2025
Vancomycin-Teixobactin Conjugates.
Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- PK/PD study of vancomycin in enterococcal infections: efficacy and safety assessment under the guidance of TDM.Microbiology spectrum · 2026Observational
- Deep metagenomics uncovers functional adaptations and pathogenic risks in the gut microbiome of Antarctic fur seals (Arctocephalus gazella).Environmental microbiome · 2026Article
- Article
- Bacterial cell envelope-targeting antibiotics.Nature reviews. Microbiology · 2026Review
- Ag-CuO Nanozymes Superior to Commercial Silver-Based Dressings: Synergistic Antibacterial Therapy via PTS-Mediated Starvation and Cuproptosis-Like Death.Research (Washington, D.C.) · 2026Article
- Bacteria-Targeted Single-Atom Nanozyme With Photothermal-Augmented Multi-Enzymatic Cascade and NO Delivery for Enhanced Infected Wound Healing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Strategies Used for the Discovery of New Microbial Metabolites with Antibiotic Activity.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vancomycin continues to be a widely used antibiotic of last resort in treating drug-resistant pathogens despite the emergence of vancomycin-resistant strains such as vancomycin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.